NURLF (Neural Therapeutics) 12-1 Month Momentum %: N/A% (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics 12-1 Month Momentum %?

Neural Therapeutics NURLF 12-1 Month Momentum % is N/A% as of Sep. 17, 2026. The stock has 1 warning sign investors should review. Among 1,354 Biotechnology companies, Neural Therapeutics ranks worse than 62.56% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-17), Neural Therapeutics's 12-1 Month Momentum % is N/A%.

The industry rank for Neural Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

NURLF's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -19.845
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Neural Therapeutics  (OTCPK:NURLF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Neural Therapeutics 12-1 Month Momentum % Related Terms

Neural Therapeutics  (OTCPK:NURLF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
Neural Therapeutics (NURLF) has a 12-1 Month Momentum % of N/A% as of Sep. 17, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #847 out of 1354 companies in the Biotechnology industry, placing it in the top 62.6%.
Is Neural Therapeutics' 12-1 Month Momentum % too high?
Neural Therapeutics' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Neural Therapeutics ranks #847 out of 1354 companies in the Biotechnology industry, which is below the industry midpoint.
How does Neural Therapeutics' 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #847 out of 1354 companies for 12-1 Month Momentum %. This places Neural Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current 12-1 Month Momentum % is N/A% as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.